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Dendritic cells (DCs) contribute to islet inﬂammation and its progression to diabetes in NOD mouse model and human. DCs
play a crucial role in the presentation of autoantigen and activation of diabetogenic T cells, and IRF4 and IRF8 are crucial genes
involved in the development of DCs. We have therefore investigated the expression of these genes in splenic DCs during diabetes
progressioninNODmice.WefoundthatIRF4expressionwasupregulated insplenocytes andinsplenicCD11c+ DCsofNODmice
as compared to BALB/c mice. In contrast, IRF8 gene expression was higher in splenocytes of NOD mice whereas its expression
was similar in splenic CD11c+ DCs of NOD and BALB/c mice. Importantly, levels of IRF4 and IRF8 expression were lower in
tolerogenic bone marrow derived DCs (BMDCs) generated with GM-CSF as compared to immunogenic BMDCs generated with
GM-CSF and IL-4. Analysis of splenic DCs subsets indicated that high expression of IRF4 was associated with increased levels of
CD4+CD8α−IRF4+CD11c+ DCs but not CD4−CD8α+IRF8+CD11c+ DCs in NOD mice. Our results showed that IRF4 expression
wasup-regulated inNOD miceandcorrelated withtheincreased levelsofCD4+CD8α− DCs,suggestingthatIRF4 maybe involved
in abnormalDC functions in type 1 diabetes in NOD mice.
1.Introduction
Dendritic cells (DCs) are professional antigen presenting
cells (APCs) that play a key role in the induction of innate
and adaptive immunity [1]. DCs recognize various path-
ogens and their components through pattern-recognition
receptors, such as TLRs. Captured pathogens are processed
and presented as antigenic peptides associated with MHC
molecules to T cells. Consequently, DCs/T cell interaction
leads to Th1 or Th2 responses and also to tolerance by
inducing Treg diﬀerentiation. The great diversity of immune
responsesfollowingDCsantigenpresentationisattributedto
the presence of multiple DCs subsets [2, 3]. At least six DCs
subsets have been identiﬁed in the mouse spleen including
conventional CD11chigh DCs and CD11cintB220+CD11b−
plasmacytoid DCs (pDCs) [4]. Conventional CD11chigh are
dividedintothree distinctsubtypes, CD4+CD8α−CD11bhigh,
CD4−CD8α+CD11blow,a n dC D 4 −CD8α−CD11bhigh [4–7].
Conventional lymphoid CD8α+ and myeloid CD8α−DCs
are the major producers of IL-12 whereas pDCs are the
producers of type I IFN [5–7]. Despite much progress in
understanding the biology of DCs, molecular events that
specify DC development and functions are not fully under-
stood. Interferon regulatory factors 4 and 8 (IRF4and IRF8),
two members of the IRF transcription factor family involved
in the regulation of both innate and adaptive immunity
[8], have been shown to contribute to DCs development
and function [9–13]. Notably, IRF4 has been shown to
be required for the development of CD11bhighCD8α− DCs
subset [13], whereas IRF-8 is required for diﬀerentiation
of CD11c+CD11blowCD8α+ DCs and pDCs subsets [14].
Indeed, mice lacking the IRF4 gene have selective defect
in splenic CD11bhighCD8α− conventional DCs [13]w h e r e a s
IRF8−/− mice have a defect in both lymphoid and plas-
macytoid DC subsets [14]. Furthermore, CD8α+ DCs and
pDCs express high levels of IRF8, but low level of IRF4.
Conversely, IRF4 expression is high in CD4+ DCs and
CD4−CD8α−CD11bhigh DCswhereas IRF8expression islow.2 Clinical and Developmental Immunology
The Nonobese Diabetic (NOD) mouse spontaneously
develops diabetes between 15 to 20 weeks of age. The onset
of the disease is preceded by a period of insulitis during
which the islets of Langerhans are inﬁltrated by autoreactive
T cells and APCs [15]. Interestingly, DCs are the ﬁrst cells
to inﬁltrate the islets [16], preceding T cell inﬁltration
[17]. Inﬁltrating DCs produce cytokines such as IL-12 [17],
suggesting their implication in the early pathogenesis of
diabetes. Furthermore, the administration of IL-12 to NOD
mice results in enhanced DCs accumulation in pancreatic
islets and accelerated diabetes onset [18]. Although the
precise mechanism leading to the breakdown of tolerance
to islets antigen is not fully understood, defects in function
and maturation of DCs in NOD mice have been suggested
[19]. Several studies have shown several abnormalities in
BM-derived and splenic DCs of NOD mice as compared to
DCs of diabetes-resistant mice [20, 21]. For example, it has
been reported that the number of splenic CD8α+ DCs and
CD8α− DCs in NOD mice is low as compared to those of
the diabetes-resistant B10.BR and C57BL6J mice [22]. This
decreased population of DCs could result in their reduced
ability to take up and to clear dead cells [14] and to maintain
self-tolerance [23].
In the present study, we have investigated the expression
of IRF4 and IRF8 genes in splenocytes and DCs of diabetes-
prone NOD mice and compared the results to diabetes-
resistant NOR and BALB/c mice. We found an upregulated
expression of IRF4 in the total splenic cell population of
NOD mice as compared to BALB/c mice. Enhanced IRF4 ex-
pression was found in CD11c+ splenic DCs of NOD as com-
p a r e dt oB A L B / cm i c e .H o w e v e r ,I R F 4a n dI R F 8e x p r e s s i o n
was only increased in BMDCs generated with a combination
of IL-4 and GM-CSF whereas their expression was low in
BMDCs generated with GM-CSF alone.
2.Materialsand Methods
2.1.Mice. MaleandfemaleNOD,NOR,C57BL/6J,CD1,and
BALB/c mice were purchased from the Jackson Laboratories
(Bar Harbor, ME). All mice were housed and bred in-
houseunderspeciﬁc pathogen-freeconditionsandwereused
according to guidelines of the Institutional Animal Care
Committee of the University of Sherbrooke.
2.2.Cell Lines and Antibodies. Anti-CD8α-PE (clone53-6.7),
anti-CD4-FITC/biotin/APC (clone GK1.5), anti-CD11c-FITC/
biotin (cloneHL3) antibodies, and streptavidin-PerCP (used
for all biotin conjugated antibodies) were from Becton-
Dickinson(San Jose, CA).The anti-IRF4-biotin (cloneM17)
and anti-IRF8-biotin (clone C19) were from Santa Cruz Bi-
otechnology (Santa Cruz, CA). The antigoat-HRP antibody
was from R and D Systems (Minneapolis, MN).
2.3. Splenic DCs Isolation. DCs puriﬁcation was performed
using antibody-coated magnetic beads from Miltenyi Biotec
(BergischGladbach,Germany)asbefore[24].Brieﬂy,spleens
weredigestedwithcollagenaseD(2or3organs),stainedwith
anti-CD11c-coated beads and sorted by MACS (Miltenyi
Biotec). Purity of CD11c+ DCs was >85% as determined by
FACS.
2.4. Generation of Bone Marrow-Derived DCs. BMDCs were
generated with GM-CSF (5ng/mL) alone or in combination
with IL-4 (4.5ng/mL) (Cederlane, Burlington, ON) as
described [25, 26]. On Day 7, DCs were collected for further
analysis.
2.5. Real-Time PCR. Total RNA was extracted from DCs
using the TRIzol reagent (Invitrogen, Carlsbad, CA). Two
micrograms of RNA were reversely transcribed to cDNA
using Superscript II (Invitrogen Burlington, ON). Quantita-
tive PCR reactions were performed using Rotor-Gene 3000
(CorbettLifeScience,Mortlake,NewSouthWales, Australia)
with a 25μL mixture composed of 2μL of cDNA template,
2μLP C Rb u ﬀer, 2μL of dNTP (10mmol/L), 0.3μLo fe a c h
primer (20pmol/mL), 0.5μL SYBR green Quantitect SYBR
Green qPCR kit(Qiagen),and 0.1μLo fT a qp o l y m e r a s e .T h e
reactions were carried out with an initial denaturation at
95◦C for 5min, followed by 40 cycles of 30s at 95◦C, 30s
at 58◦C, and 30s at 72◦C. Ampliﬁcationplotswere generated
using the Rotor-Gene Ampliﬁcation software v6.0 (Corbett
Research). HPRT was used as a reference to obtain the rela-
tive fold change for target samples using the comparative CT
method. The primers used were 5  AATGGGAAACTCCGA-
CAGTG3  (IRF4 sense), 5  TAGGAGGATCTGGCTTGT-
CG3  (IRF4 antisense), 5  GATCGAACAGATCGACAG-
CA3  (IRF8 sense), 5  AGAGCACAGCGTAACCTCGT3 
(IRF8 antisense), 5  GTTGGATACAGGCCAGACTTTGTT-
G3  (HPRTsense), and5  GATTCAACTTGCTCTCATCTT-
AGGC3  (HPRT antisense).
2.6. Western Blots. BM-derived and splenic DCs were har-
vested, washed in cold PBS, and resuspended in lysis buﬀer
containing Tris 50mM, NaCl 0.15M, DTT 1mM, Triton X-
100 1% (v/v), and a cocktail of protease and phosphatase
inhibitors. Cell lysates were fractionated on 10% SDS-PAGE
gels, transferred to a nitrocellulose membrane (Hybond-
ECL Amersham Biosciences, Baie d’Urf´ e, QC) and incu-
bated overnight with primary antibodies, followed by the
appropriate secondary antibodies and revealed by enhanced
chemiluminescence (GE Health Care, Baie d’Urf´ e, QC).
Quantiﬁcation of Western bandintensities was performed by
densitometry analysis of X-ray ﬁlms using the NIH Image
software (http://rsb.info.nih.gov/nih-image/).
2.7. Flow Cytometry. Cells were washed once with PBS sup-
plemented with 2.5% bovine serum albumin(PBS-BSA)and
incubated with the indicated mAbs for 20min at 4◦C. In
the case of IRF4 and IRF8 intracellular staining, the cells
were ﬁxed with 4% paraformaldehyde for 1h at 4◦C, per-
meabilized with FACS buﬀer containing 0.1% saponin and
stained with anti-IRF4 or IRF8 Abs or antirat IgG2a for
30min at 4◦C. The cells were then washed twice with PBS-
BSA and analyzed by FACS using the CellQuest software
(BD Biosciences) or the FCS express V3 software (De Novo
Software, Los Angeles, CA).Clinical and Developmental Immunology 3
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Figure 1: Age-related IRF4 and IRF8 mRNA expression levels in splenocytes of diabetes-prone and diabetes-resistant mice. Total splenic
RNA was obtained from NOD, NOR, C57BL/6J,CD-1, andBALB/c mice, puriﬁed and gene expression proﬁleof IRF4 (a) andIRF8 (b) were
analyzed by real time RT-PCR. Each RNA sample was analyzed in triplicates and normalized to HPRT expression (ΔCt). Each NOD sample
was normalizedto a BALB/c sample(ΔΔCt = ΔCt sample −ΔCt BALB/c) and, the expression level wascalculated as follows:2−ΔΔCt.D a t aa r e
shownas the average ± SD of 4 independent experiments (∗P<. 05, ∗∗P<. 01 and ∗∗∗P<. 001).
2.8. Statistical Analysis. Two groups were compared using
two-tailed unpaired Student’s t test. When more that two
groups were compared, one-way ANOVA Dunnett’s test for
multiple comparisons was used. Diﬀerences were considered
to be statistically signiﬁcant when a P<. 05. Data reported
here are representative of 2-3 independent experiments.
Histograms and bar graph results are shown as the mean ±
SEM.
3.Results
3.1. IRF4 But Not IRF8 Gene Expression Is Increased in
Splenocytes of NOD Mice. In a ﬁrst series of experiments,
we used quantitative PCR (qPCR) to assess gene expression
of IRF4 and IRF8 in splenocytes isolated from prediabetic
and diabetic NOD mice as well as control diabetes-resistant
congenic NOR and BALB/c mice. We found that the levels of
mRNA expression of IRF4 were slightly but not signiﬁcantly
higher (P>. 05) in splenocytes of 3-week old NOD (7.7 ±
0.8) mice as compared to splenocytes of diabetes-resistant
BALB/c(1.04±0.1),NOR(2.6±0.6),C57BL/6(5.8±0.9),or
CD1(3.7±0.8)mice(Figure 1(a)). The levelsofIRF4mRNA
expression were signiﬁcantly (P<. 001) increased in the
splenocytes of 7-, 10-, and 20-week old diabetic NOD mice
(54.8 ± 1.9a n d5 8 .9 ± 16.1, resp.) as compared with 3 weeks
old NOD mice and diabetes-resistant mice (Figure 1(a)).
However, the expression of IRF4 remained unchanged in the
splenocytes of 3-, 6-, 10-, or 20-week old NOR and BALB/c
mice (data not shown). Interestingly, IRF4 gene expression
in splenocytes of nondiabetic 20-week old NOD mice was
signiﬁcantly lower (P<. 05) than in 20-week old diabetic
NOD mice (20±5.3c o m p a r e dt o5 3 .9±16.1) (Figure 1(a)).
AnalysisofIRF8geneexpression revealedsimilarlevelsof
IRF8 mRNA in splenocytes of BALB/c and 3-week old NOD
mice (0.9 ± 0.1 as opposed to 1.1 ± 0.1) (Figure 1(b)). In
addition, IRF8 gene expression was signiﬁcantly (P<. 05)
increased in the splenocytes of 7-, 10-, and 20-week old
NOD mice (Figure 1(b)). In contrast, the levels of IRF8 gene
expression were similar in the splenocytes of 20-week old
nondiabetic and diabetic NOD mice (3.8 ± 0.6 as opposed
to 3.8 ± 1.1) (Figure 1(b)).
We next determined whether changes observed in the
expression of the IRF4 and IRF8 genes were matched by
c h a n g e sa tt h ep r o t e i nl e v e l s .T o t a lp r o t e i n se x t r a c t sw e r e
preparedfromthesplenocytesofNODandBALB/cmiceand
the expression of IRF4 and IRF8 was analyzed by Western
blots (Figure 2). Results showed that IRF4 expression was
signiﬁcantly higher (P<. 05) in splenocytes of 3-week old
NOD mice than in BALB/c mice (1.38 ± 0.08 as opposed to
1.00±0)(Figures2(a)and2(b)).IRF4expressionwas slightly
but not signiﬁcantly (P>. 05) higher in 7-, 10-, and 20-week
old nondiabetic and diabetic NOD mice (1.58± 0.02, 1.60 ±
0.1, 1.52 ± 0.03, and 1.81 ± 0.10, resp.) as compared to IRF4
expression in 3-week old NOD mice (Figures 2(a) and 2(b)).
Incontrast,theproteinlevelsofIRF8insplenocytesof3-and
7-week-old NOD mice were similar to those of BALB/c mice
(1.09 ± 0.1, 0.98 ± 0.10 as compared to 1.00 ± 0, P>. 05).
Protein levels of IRF8 were signiﬁcantly higher (P<. 05) in
10- and 20-week-old non diabetic and diabetic NOD mice
(1.16 ± 0.1, 1.22 ± 0.03, and 1.25 ± 0.10, resp.) as compared
to BALB/c (1.00 ± 0) mice (Figures 2(c) and 2(d)). Together,
theseresultssuggestedthatgeneandproteinexpressionlevels
of IRF4 were upregulated in the spleen of diabetes-prone
NOD mice whereas levels of IRF8 remained unchanged at4 Clinical and Developmental Immunology
BALB/c Diabetic
20
weeks
10
weeks
7
weeks
3
weeks
NOD
IRF4
β-actin
(a)
B
A
L
B
/
c
D
i
a
b
e
t
i
c
20
weeks
10
weeks
7
weeks
3
weeks
NOD
0
0.5
1
1.5
2
I
R
F
4
/
β
-
a
c
t
i
n
∗
∗∗
∗∗
∗∗
∗∗
(b)
BALB/c Diabetic
20
weeks
10
weeks
7
weeks
3
weeks
NOD
IRF8
β-actin
(c)
B
A
L
B
/
c
D
i
a
b
e
t
i
c
20
weeks
10
weeks
7
weeks
3
weeks
NOD
0
0.5
1
1.5
I
R
F
8
/
β
-
a
c
t
i
n
ns
ns
∗
∗
∗∗
(d)
Figure 2: Age-related IRF4 and IRF8 expression levels in splenocytes of diabetes-prone NOD mice and diabetes-resistant BALB/c mice.
Proteins were extracted from NOD or BALB/c mouse splenocytes and analyzed by Western blotting for IRF4 (a) or IRF8 (c) expression. The
relative intensities of the bands were determined using the NIH Image software and normalized to reference actin bands to establish a ratio
of (b) IRF4/actin and (d) IRF8/actin. The levels of expression in BALB/c mice were arbitrarily set at a unitary value. Data are representative
of 3 independent experiments.
3a n d7w e e k so fa g e ,a n dw e r es l i gh t l yi n c r e a s e di n1 0a n d2 0
weeks old mice when compared to BALB/c mice.
3.2. Increased Expression of IRF4 Correlated with Augmented
CD4+CD8α−CD11c+ Splenic DCs in NOD Mice. To deter-
mine whether diﬀerential expression of IRF4 and IRF8 in
splenocytes of NOD mice resided in splenic DCs, we exam-
ined the levels of protein expression of IRF4 and IRF8 by
Westernblotsin CD11c+-puriﬁed splenic DCsof8-week-old
NOD and BALB/c mice. Results showed (Figure 3(a))t h a t
the expression of IRF4 was higher in splenic DCs of NOD
mice as compared to BALB/c mice (P<. 05). In contrast,
IRF8 expression was similar in splenic DCs of both strains
of mice (Figure 3(b)). Since IRF4 and IRF8 have been shown
to be essential for the development of CD4+CD8α−CD11c+
and CD4−CD8α+CD11c+ subsets, respectively [9], we deter-
mined whether the changes observed in IRF4 and IRF8
expression in splenic DCsof NODand BALB/c mice aﬀected
the proportions of these two DCs subsets. Results of FACS
analysis (Figure 3(c))s h o w e dn od i ﬀerence in the percentage
of CD4+CD8α−IRF4+CD11c+ DCs subset in splenocytes of
3-week-oldNODandBALB/cmice(0.42%±0.03asopposed
to 0.27% ± 0.03, P>. 05). The percentages of splenic
CD4+CD8α−IRF4+CD11c+ DCs subset were signiﬁcantly
(P<. 05) increased in 7-, 10-, and 20-week-old NOD
mice (0.60% ± 0.030 at 7 weeks, 0.63% ± 0.03 at 10Clinical and Developmental Immunology 5
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Figure 3: Expression of IRF4 in splenic DCs of diabetes-prone NOD mice and diabetes-resistant BALB/c mice. Proteins were extracted from
CD11c+-puriﬁed splenicDCsfromNODandBALB/cmiceandanalyzedbyWesternblottingfor(a)IRF4or(b)IRF8expression.Therelative
intensitiesofthebands were assessedusingtheNIHImagesoftwareandnormalizedto reference actin bands to establisharatio ofIRF4/actin
(a), lower panel) and (b), lower panel) IRF8/actin. The expression levels observed in BALB/c were arbitrarily set as a unitary value. Data are
representative of 2 independent experiments (Exp1 and Exp2). (c) and (d) splenocytes from NOD and BALB/c mice were stained for the
CD11c, CD4, and CD8α surface markers in combination with intracellular staining with an anti-IRF8 or anti-IRF4 mAb and analyzed by
ﬂow cytometry. Data represent the average percentage of CD11c+CD4+CD8α−IRF4+-positive (c) and CD11c+CD4−CD8α+IRF8+-positive
(d) cells of two independent experiments. Error bars correspond to the averages ±S.D (∗P<. 05, ∗∗P<. 01 and ∗∗∗P<. 001).
weeks, and 0.60% ± 0.07 at 20 weeks) as compared to 3
weeks old (NOD 0.42% ± 0.03) and BALB/c (0.27% ± 0.0)
mice. In addition, there were no signiﬁcant diﬀerence in
splenic CD4+CD8α−IRF4+CD11c+ DCs subset in 7-, 10-,
and 20-week-old nondiabetic and diabetic NOD mice. In
contrast, an absence of diﬀerences was noted in the per-
centage of CD4−CD8α+IRF8+CD11c+ DCs subset in the
splenocytes of BALB/c mice and diabetic or nondiabetic
NOD mice (Figure 3(d)). Together, these data suggested that
high expression of IRF4 in NOD mice was associated with
enhancedsplenicCD4+CD8α−IRF4+CD11c+ DCssubsetbut
not with splenic CD4−CD8α+IRF8+CD11c+ DCs subset.6 Clinical and Developmental Immunology
3.3. Increased Expression of IRF8 and IRF4 in BMDCs of
NOD Mice. Defects in phenotype and tolerogenic function
of BMDCs of NOD mice have also been associated with
diabetes [20, 21]. We have reported that treatment of NOD
mice with GM-CSF restored the tolerogenic function of
myeloid DCs [24]. In addition, BMDCs generated with
low dose of GM-CSF possessed tolerogenic functions when
comparedtoimmunogenicBMDCsgeneratedwith GM-CSF
and IL-4 [27] (Guindi et al., unpublished data). Therefore,
we determined the expression IRF4 and IRF8 in BMDCs of
NOD mice generated with GM-CSF or with a combination
of GM-CSF and IL-4. BMDCs generated from BALB/c mice
were used as controls. Under both sets of experimental
conditions, more than 95% of BMDCs were CD8α−CD11c+
cells. Results showed that BMDCs generated with GM-CSF
from both strains of mice expressed similar levels of IRF4
as determined by qPCR (Figure 4(a)) and by Western blot
(Figures 4(b) and 4(c)). IRF4 expression was increased in
BMDCs generated with a combination of GM-CSF and
IL-4 and was signiﬁcantly higher (P<. 05) in NOD as
compared to BALB/c mice (Figures 4(a), 4(b) and 4(c)). The
expression of IRF8 was similar in BMDCs of both strain of
mice generated with GM-CSF (Figures 4(d), 4(e) and 4(f)).
However, BMDCs generated with a combination of GM-
CSF and IL-4 expressed signiﬁcantly (P<. 05) higher levels
of IRF8 as compared to BMDCs generated with GM-CSF.
Importantly, the levels of expression of IRF8 were higher
in the case of immunogenic BMDCs generated with GM-
CSF and IL-4 from NOD than in the case of BALB/c mice
(Figures 4(d), 4(e) and 4(f)). Together, these results showed
that IRF4 and IRF8 were highly expressed in immunogenic
BMDCs generated with a combination of GM-CSF and IL-4
in the case of both strains of mice, whereas their expression
was signiﬁcantly lower in the case of tolerogenic BMDCs
generated with GM-CSF alone.
4.Discussion
In this study, RNA gene expression and protein analysis
were used to investigate the expression proﬁle of the two
transcription factors IRF4 and IRF8 that are known to play
an important role in DCs diﬀerentiation [9–13]. We found
that the expression of IRF4 was enhanced in splenic DCsand
in immunogenic BMDCs but not in tolerogenic BMDCs of
NOD mice. The increased IRF4 expression was associated
with a greater percentage of CD4+CD8α−IRF4+CD11c+ DCs
but not CD4−CD8α+IRF8−CD11c+ DCs. In contrast, IRF8
expression remained unchanged in splenic DCs of NOD and
diabetes-resistant BALB/c mice although it was signiﬁcantly
increased in immunogenic BMDCs but not in tolerogenic
BMDCs of NOD mice.
Development of type 1 diabetes consists in a succession
of events during which variation in gene expression plays
a critical role in progression from islet inﬂammation to
clinical diabetes [28, 29]. The development of microarray
technology has provided a new approach to understand
diabetes pathogenesis and to identify genes deregulated in
type 1 diabetes including NOD mice [29, 30]. IRF4 is one
candidate gene located in the idd14 susceptibility region
suspected toplay a role in the developmentoftype 1diabetes
in NOD mice [29]. IRF8, another candidate gene important
in regulating Th2 immune response, has been suggested to
play an important role in diabetes development [29]. Here,
we found high levels of mRNA and protein expression of
IRF4inspleniccellsofNODmicewhencomparedtoBABL/c
mice. IRF4 expression was particularly found to increase in
7 weeks and older NOD mice in which islet inﬂammation
has already occurred and in diabetic NOD mice. These
results suggested that up-regulation of IRF4 expression may
play an important role in diabetes development in diabetes-
prone NOD mice. Our results could not be explained by
triggering immune response toward Th1 response. In this
connection, several studies have reported that diabetes in
NOD mice is a Th1-mediated disease and that immuno-
deviation toward a Th2 response contributes to prevention
of diabetes development [31–34]. Of note, IRF4 has been
shown to be essential for the Th2 response, and na¨ ıve
T cells of mice deﬁcient for IRF4 have a compromised
production of IL-4 and Th2 cytokines [35]. Alternatively,
the increased IRF4 expression during islet inﬂammation
and diabetes development in NOD mice could be also
explained by the requirement of IRF4 for production and
responsiveness to IL-21 and for stabilization of the Th17
phenotype [36–38]t h a th a sb e e ns h o w nt ob ec r i t i c a lf o rt h e
development of type 1 diabetes [39]. This observation may
also explain the reduced expression of IRF4 in 20-week-old
nondiabetic NOD mice as opposed to 20-week-old diabetic
NOD mice. In contrast, the increased IRF8 expression in the
spleen of diabetes-prone NOD mice may be the result of a
high production of IFNγ which is known to induce IRF8
expression in macrophages and T cells [40].
IRF4 and IRF8 play a key role in molecular programs
regulating DCsdevelopmentand function[9–13].Abnormal
DCs development and function have been reported to be
associated with diabetes in human and in NOD mice [20, 21,
41].Here,wefound thatsplenicDCsofNODmiceexpressed
high levels of IRF4 when compared to DCs of nondiabetic
NODmiceand BALB/cmice, whereas theexpression ofIRF8
was similar in splenic DCs of NOD and BALB/c mice. The
expression of IRF4 in NOD mice was associated with an
increase in the number of the CD4+CD8α−IRF4+CD11c+
DCs subset, thereby conﬁrming that IRF4 contributed to
the developmentofCD4+CD11c+ DCs[9, 42]. Furthermore,
our data suggested that increases in IRF4 expression and
CD4+CD8α−CD11c+IRF4+ DCs population in NOD mice
were associated with the abnormal function of DCs in
diabetes-prone NODmice.Severalstudieshavealsoreported
an abnormal function of bone marrow-derived DCs of NOD
mice generated with a combination of GM-CSF and IL-4.
For instance, it was found that the enhanced capacity to
activate autoreactive T cells and the increased production
of IL-12p70 contributed to the development of diabetes in
NOD mice [43, 44]. We also observed that BMDCs of NOD
mice, generated with GM-CSF were less immunogenic than
BMDCs generated with a combination of GM-CSF and IL-4
(Guindi et al. submitted). This observation prompted us
to compare the expression of IRF4 and IRF8 in BMDCsClinical and Developmental Immunology 7
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Figure 4: Reduced expression of IRF4 and IRF8 in tolerogenic BMDCs derived from NOD mice. Total RNA was extracted from BM-DCs
generated with GM-CSF or a combination of GM-CSF and IL-4, puriﬁed and gene expression proﬁles of IRF4 (a) and IRF8 (d) were
analyzedby RT-PCR. Each samplewasanalyzedintriplicates andnormalizedto HPRT expression(ΔCt).Each NOD samplewasnormalized
to BALB/c sample (ΔΔCt = ΔCt sample −ΔCt BALB/c), and the expression levels were calculated as follows: 2−ΔΔCt.D a t aa r es h o w na st h e
average ±SD of 3-4 independent experiments (∗P<. 05 and, ∗∗P<. 01). (b) and (e) total proteins were extracted from BM-DCs generated
with GM-CSF or a combination of GM-CSF and IL-4 and analyzed by Western blotting for IRF4 (b) or IRF8 (f) expression. The relative
intensitiesofbands were assessedusingtheNIH Imagesoftwareandnormalizedto reference actin bands to establisharatio of(c) IRF4/actin
and (f) IRF8/actin. The expression levels observed in BALB/c mice were arbitrarily set as a unitary value. A representative of 2 independent
experiments is shown.Error bars correspond to S.D.8 Clinical and Developmental Immunology
generated with GM-CSF and with a combination of GM-
CSF and IL-4. IRF4 and IRF8 were less expressed in BMDCs
generated with GM-CSF whereas they were more expressed
inBMDCsgeneratedwithGM-CSFand IL-4,suggesting that
downregulation of IRF4 and IRF8 may attenuate abnormal
immunogenic function of BMDCs in NOD mice. In support
of this interpretation, several studies have reported that
IRF8 contributes to the production of IL-12p70 by acting
as transcriptional activator of the IL-12p35 and IL-12p40
genes [45–48]. Therefore, our ﬁndings of high expression
of IRF8 in DCs of NOD mice may explain their abnormal
high production of IL-12p70. Our data also suggested that
increased levels of IRF4 in DCs contribute to their abnormal
function in NOD mice. In support of this interpretation, the
transcription of IRF4 has been shown to be regulated by NF-
κB elements located in the IRF4 promoter region that bind
Rel/NF-κBc o m p l e x e s[ 49]. In this context, increased NF-κB
activation has been reported to display essential functions
of BMDCs for the development of type 1 diabetes [50].
Therefore, enhanced NF-κBa c t i v a t i o ni nD C so fN O Dm i c e
leading to their hyperactivation may result from upregulated
IRF4 expression.
Our data reported an enhanced involvement of the IRF4
and IRF8 in DCs function in type 1 diabetes-susceptible
NOD mice as opposed to control, nondiabetic mice. Further
investigation on the role of IRF4 and IRF8 in diabetes
development may help to determine whether IRF4 and/or
IRF8 could be potential targets for therapeutic interventions
in type 1 diabetes.
Abbreviations
DCs: Dendritic cells
BMDCs: Bone marrow-derived dendritic cells
GM-CSF: Granulocyte macrophage-colony stimulating
factor
IRF: Interferon regulating factor.
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